ArticleJournal of Alzheimer's disease : JAD2010
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.
Article in Journal of Alzheimer's disease : JAD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.PLoS genetics · 2014Pooled it
- Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.Brain imaging and behavior · 2014Pooled it
- Artificial Intelligence, Machine Learning and Deep Learning in Ion Channel Bioinformatics.Membranes · 2021Review
- Single Nucleotide Polymorphisms in Alzheimer's Disease Risk Genes Are Associated with Intrinsic Connectivity in Middle Age.Journal of Alzheimer's disease : JAD · 2020Article
- Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes.Journal of Alzheimer's disease : JAD · 2020Article
- TheScience translational medicine · 2019Article
- Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.Acta neuropathologica · 2017Article
- SORL1 gene, plasma biomarkers, and the risk of Alzheimer's disease for the Han Chinese population in Taiwan.Alzheimer's research & therapy · 2016Article
- Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.BMC neurology · 2016Article
- CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice.Scientific reports · 2016Article
- Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits.Scientific reports · 2016Article
- CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain.Journal of cell science · 2015Article
- 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Review
- Alzheimer's disease risk genes and mechanisms of disease pathogenesis.Biological psychiatry · 2015Review
- Genetic discoveries in AD using CSF amyloid and tau.Current genetic medicine reports · 2014Article
- Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca2+ and Aβ levels.PloS one · 2014Article
- The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013Review
- GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.Neuron · 2013Article
- CALHM1 controls the Ca²⁺-dependent MEK, ERK, RSK and MSK signaling cascade in neurons.Journal of cell science · 2013Article
- The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.PLoS genetics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Recent large-scale genetic studies of late-onset Alzheimer's disease have identified risk variants in CALHM1, GAB2, and SORL1. The mechanisms by which these genes might modulate risk are not definitively known. CALHM1 and SORL1 may alter amyloid-β (Aβ) levels and GAB2 may influence phosphorylation of the tau protein. In this study we have analyzed disease associated genetic variants in each of these genes for association with cerebrospinal fluid (CSF) Aβ or tau levels in 602 samples from two independent CSF series. We failed to detect association between CSF Aβ42 levels and single nucleotide polymorphisms in SORL1 despite substantial statistical power to detect association. While we also failed to detect association between variants in GAB2 and CSF tau levels, power to detect this association was limited. Finally, our data suggest that the minor allele of rs2986017, in CALHM1, is marginally associated with CSF Aβ42 levels. This association is consistent with previous reports that this non-synonymous coding substitution results in increased Aβ levels in vitro and provides support for an Aβ-related mechanism for modulating risk for Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.